學門類別
哈佛
- General Management
- Marketing
- Entrepreneurship
- International Business
- Accounting
- Finance
- Operations Management
- Strategy
- Human Resource Management
- Social Enterprise
- Business Ethics
- Organizational Behavior
- Information Technology
- Negotiation
- Business & Government Relations
- Service Management
- Sales
- Economics
- Teaching & the Case Method
最新個案
- A practical guide to SEC ï¬nancial reporting and disclosures for successful regulatory crowdfunding
- Quality shareholders versus transient investors: The alarming case of product recalls
- The Health Equity Accelerator at Boston Medical Center
- Monosha Biotech: Growth Challenges of a Social Enterprise Brand
- Assessing the Value of Unifying and De-duplicating Customer Data, Spreadsheet Supplement
- Building an AI First Snack Company: A Hands-on Generative AI Exercise, Data Supplement
- Building an AI First Snack Company: A Hands-on Generative AI Exercise
- Board Director Dilemmas: The Tradeoffs of Board Selection
- Barbie: Reviving a Cultural Icon at Mattel (Abridged)
- Happiness Capital: A Hundred-Year-Old Family Business's Quest to Create Happiness
Novartis Pharmaceuticals Corp: Redefining Success in the U.S. (B)
內容大綱
This (B) case describes the actions Andre Wyss, President of Novartis Pharmaceuticals Corp., took in early 2012 to transform the company's General Medicines group and build its speciality medications marketing the selling capabilities in the face of falling revenues and an imminent workforce reduction. Rather than downsize the organization quickly to save costs, Wyss and his team took a different approach. They told the organization's employees that there would be a significant workforce reduction but it would not occur for several months. In the meantime, Wyss asked the employees to help build the new capabilities and put processes in place to support the move into specialty medications. It was a bold decision and defied convention.